



CURRICULUM VITAE

Nombre: Emilio Gámez-Ugalde

Educación Universidad/ Escuela de Medicina

1978-1981	Residencia en Oncología y Radioterapia Centro Médico Nacional Siglo XXI, Hospital de Oncología. México D.F.
1976-1978	Residencia en Medicina Interna. Hospital General, Instituto Mexicano del Seguro Social
1967-1973	Médico Cirujano, Facultad de Medicina Universidad Autónoma de San Luis Potosí.

**Especialidad(es) (Especialidad,
año):**

Oncología	1981
Medicina Interna	1978

Puestos Post Graduación

1994 al presente	Jefe del Departamento de Oncología y Radioterapia
1987-1993	Médico Adjunto en Oncología, y Oncoginecología, Hospital Central
1987-2001	Médico Adjunto en Unidad de Oncología, Centro Médico
1981-1987	Jefe del Departamento de Oncología Hospital de Especialidades #25, Monterrey NL, México

Puesto Actual

Jefe del Departamento de Oncología y Radioterapia

**Experiencia en Pruebas Clínicas Como Investigador Principal
(Institutos, indicaciones, de-a):**

- A Double-blind Study to compare 2 medications in the prevention of moderately emetogenic Chemotherapy-induced nausea and vomiting. 2001.
- A Double-blind Study to compare 2 medications in the prevention of highly emetogenic Chemotherapy-induced nausea and vomiting. 2001.



- A Multicenter, Open-label Study to assess the safety and efficacy of a medication for the prevention of Chemotherapy-Induced nausea and vomiting in repeated chemotherapy cycles. 2001.
- A Double-blind Study to compare 2 medications in the Treatment of PS = 2 Patients with Chemotherapy Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) A Phase III Study 2004
- A Double-blind Study to compare 2 medications in the Treatment of Patients with Advanced Breast Cancer A Phase III Study 2005
- A Multicenter, Open-label Study to compare 2 medications in the Treatment of Patients with Advanced Renal Cell Cancer A Phase III Study 2005
- A Randomized Phase 3 Study of the efficacy and Safety of A New Treatment in Metastatic Pancreatic Adenocarcinoma Previously Treated 2006
- A phase 3 Trial to compare efficacy of 2 medications in patients with Advanced Breast Cancer (2006)
- Single Dose, Randomized, Double-blind Study to compare 3 doses in the prevention of moderately emetogenic Chemotherapy-induced nausea and vomiting 2006
- An open label, Randomized, phase 3 study to compare 2 medications in the Treatment of Patients with Advanced Cancer Gastric (2007)
- Comparative treatment in Women with NSCLC 2007
- A randomized, open-label, multicenter, phase 3 study drugs study versus supportive care in breast cancer. (2008)
- Estudio Observacional en Pacientes con Cáncer de Próstata Hormono Refractarios (In progress)
- A Randomized Phase 3 Study of the efficacy and Safety of A New Treatment in Multiple Myeloma

Publicaciones:

1. Improved Survival of Inflammatory Breast Carcinoma with combination of chemotherapy and radiotherapy. Abstracts ASCO March 1980, San Diego Cal
2. Hiperplasia Gigante de Ganglios Linfáticos, Enfermedad de Castleman: Experiencia del Hospital de Oncología CMN Siglo XXI. Arch Invest Med 117:11;1981

Firma

6 de Abril de 2010